2.08 (-%)
As of Dec 06, 2024
Source:
Maia Biotechnology, Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity.
Country | United States |
Headquarters | chicago, illinois |
Phone Number | (312) 416-8592 |
Industry | manufacturing |
CEO | Vlad Vitoc |
Website | www.maiabiotech.com |